Düzgün, Ali Cemalİlkeli, Ekin2023-07-262023-07-2620211309-3878http://doi.org/10.18521/ktd.807493https://search.trdizin.gov.tr/yayin/detay/467294https://hdl.handle.net/20.500.12684/13460Objective: This clinical study included a retrospective evaluation of 138 patients using new oralanticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) for lower extremity deep veinthrombosis.Methods: 138 patients using new oral anticoagulant drugs were included in the retrospective study.Demographic characteristics, diagnosis and treatment charts, radiological images, epicrisis notes ofthe patients were recorded. Records of each patient were reviewed during their 12 months of follow- up. New oral anticoagulant efficacy; It was evaluated by measuring thigh and calf diameters beforeand after treatment, whether there was recanalization in Doppler USG (recanalization> 75%),recanalization time, bleeding side effects and recovery times with treatment, and recurrence rates.The data were analyzed statistically using a statistics program.Results: A significant difference was found when the mean thigh diameter measurements measuredat the beginning of the treatment (Mean ± SD: 75,41) and the mean thigh diameter measured afterthe treatment (Mean ± SD: 54,63) were compared (p<0.05). A significant difference was foundwhen the mean calf diameter measurements (Mean ± SD: 43.99) measured at the beginning of thetreatment and the mean calf diameter measured after the treatment were compared (p<0.05). Post- treatment Doppler USG showed complete recanalization rate in 54% (75 patients) at 3 months and25% (35 patients) at 6 months. At the end of the 6th month, the total recanalization rate occurred in80% (110) patients.Conclusions: New oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) are veryeffective in the treatment of lower extremity deep venous thrombosis, both in providingrecanalization and in terms of clinical improvement in early and midterm.en10.18521/ktd.807493info:eu-repo/semantics/openAccessArticle132312318467294